...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Presentation is over
1
Jun 09, 2020 06:48AM
4
Jun 09, 2020 07:04AM
2
Jun 09, 2020 07:16AM
1
Jun 09, 2020 07:23AM
4
Jun 09, 2020 07:43AM
2
Jun 09, 2020 08:00AM
2
Jun 09, 2020 08:01AM
1
Jun 09, 2020 08:12AM
2
Jun 09, 2020 08:17AM
2
Jun 09, 2020 08:33AM
5
Jun 09, 2020 08:34AM
2
Jun 09, 2020 09:11AM
5
Jun 09, 2020 09:14AM
5
Jun 09, 2020 09:24AM
4
Jun 09, 2020 09:36AM
3
Jun 09, 2020 09:56AM
1
Jun 09, 2020 10:03AM
2
Jun 09, 2020 10:08AM
1
Jun 09, 2020 10:28AM
1
Jun 09, 2020 10:36AM

Jun 09, 2020 10:45AM
1
Jun 09, 2020 12:37PM
2
Jun 09, 2020 01:19PM

It looks good, agreed, but the problem with the CVD data in low GFR patients is small numbers of patients and lack of stratified randomisation (randomisation after slection on the basis of low GFR). This might be the basis for another trial to confirm the benefit.

2
Jun 09, 2020 01:29PM
Share
New Message
Please login to post a reply